Top

Gepubliceerd in:

2021 | OriginalPaper | Hoofdstuk

7. Medicamenteuze en andere biologische behandelstrategieën bij mensen met een psychotische kwetsbaarheid

Auteurs : Dr. S. K. Spoelstra, Drs. F. D. van Es, Prof. dr. L. de Haan, Prof. dr. R. Bruggeman, Dr. H. Knegtering

Gepubliceerd in: Ernstige psychiatrische aandoeningen

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

De geïndividualiseerde, multidimensionale en multidisciplinaire behandeling van mensen met psychotische verschijnselen vereist een goede behandel- en zorgcontext. Het succesvol instellen op een antipsychoticum, ter verlaging van de kans op een recidiefpsychose en een heropname, dient plaats te vinden binnen een breed psychosociaal behandelaanbod. Goede samenwerking met naasten is essentieel. Er lijken geringe verschillen in effectiviteit van antipsychotica op positieve symptomen te bestaan. In de klinische praktijk wordt de keuze voor een antipsychoticum vaak vooral gemaakt op basis van bijwerkingen en soms op basis van de beschikbaarheid van langwerkende varianten van een middel. Depotantipsychotica lijken betere langetermijneffecten te hebben dan orale varianten van dezelfde stof. Staken of verminderen van de dosis van een antipsychoticum dient zeer geleidelijk te gebeuren. Clozapine is bij therapieresistente psychosen een belangrijk middel, al dan niet in combinatie met aripiprazol. Er is beperkte evidentie voor elektroconvulsietherapie (ECT) bij therapieresistente psychosen.

vorige hoofdstuk Methodisch werken aan verandering voor mensen met EPA

volgende hoofdstuk Persisterende depressie

Aleman, A., Enriquez-Geppert, S., Knegtering, H., & Dlabac-de Lange, J. J. (2018). Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials. Neuroscience and Biobehavioral Reviews, 89, 111–118.CrossRef

Aleman, A., Lincoln, T. M., Bruggeman, R., Melle, I., Arends, J., Arango, C., et al. (2017). Treatment of negative symptoms: Where do we stand, and where do we go? Schizophrenia Research, 186, 55–62.CrossRef

Ali, S. A., Mathur, N., Malhotra, A. K., & Braga, R. J. (2019). Electroconvulsive therapy and schizophrenia: A systematic review. Molecular Neuropsychiatry, 5, 75–83.CrossRef

Barber, S., Olotu, U., Corsi, M., & Cipriani, A. (2017). Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia (Review). Cochrane Database of Systematic Reviews, 3, CD006324. https://doi.org/10.1002/14651858.cd006324.pub3.

Barker, A. T., Jalinous, R., & Freeston, I. L. (1985). Non-invasive magnetic stimulation of human motor cortex. The Lancet, 325, 1106–1107.

Bogers, J. P. A. M., Hambarian, G., Michiels, M., Vermeulen, J., & De Haan, L. (2020). Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin Open. https://doi.org/10.1093/schizbullopen/sgaa002.CrossRef

Bogers, J. P. A. M., Schulte, P. F. J., Broekman, T. G., Moleman, P., & De Haan, L. (2018). Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. European Neuropsychopharmacology, 28, 1024–1034.CrossRef

Diamond, R. J. (2011). The medication question: Weighing your mental health treatment options. New York: Norton.

Elwyn, G., Frosch, D., Thomson, R., Joseph-Williams, N., Lloyd, A., Kinnersley, P., et al. (2012). Shared decision-making: A model for clinical practice. Journal of General Internal Medicine, 27, 1361–1367.

Endler, N. S. (1988). The origins of electroconvulsive therapy (ECT). Convulsive Therapy, 4, 5–23.PubMed

Helfer, B., Samara, M. T., Huhn, M., Klupp, E., Leucht, C., Zhu, Y., et al. (2016). Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: A systematic review and meta-analysis. The American Journal of Psychiatry, 173, 876–886.

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., et al. (2019). Comparative efficacy and tolerability of 32 antipsychotic for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet, 394, 939–951.CrossRef

Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet, 382, 951–962.CrossRef

Lieberman, J. A., Safferman, A. Z., Pollack, S., Szymanski, S., Johns C. Howard, S., et al. (1994). Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. The American Journal of Psychiatry, 151, 1744–1752.

Luchini, F., Medda, P., Mariani, M. G., Mauri, M., Toni, C., & Perugi, G. (2015). Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World Journal of Psychiatry, 5, 182–192.CrossRef

Marder, S. R., Fleischhacker, W. W., Earley, W., Lu, K., Zhong, Y., Németh, G., et al. (2019). Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. European Neuropsychopharmacology, 20(1), 127–136.CrossRef

Marzouk, T., Winkelbeiner, S., Azizi, H., Malhotra, A. K., & Homan, P. (2019). Transcranial magnetic stimulation for positive symptoms in schizophrenia: A systematic review. Neuropsychobiology., 10, 1–13.

Meijel, B., Van der Gaag, M., Kahn, R. S., & Grypdonck, M. H. (2003). Relapse prevention in patients with schizophrenia: The application of an intervention protocol in nursing practice. Archives of Psychiatric Nursing, 17, 165–172.CrossRef

Petrides, G., Malur, C., Braga, R. J., Bailine, S. H., Schooler, N. R., Malhotra, A. K., et al. (2015). Electroconvulsive therapy augmentation in clozapineresistant schizophrenia: A prospective, randomized study. The American Journal of Psychiatry, 172, 52–58.

Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77.CrossRef

Sanghani, S. N., Petrides, G., & Kellner, C. H. (2018). Electroconvulsive therapy (ECT) in schizophrenia: A review of recent literature. Current Opinion in Psychiatry, 31, 213–222.CrossRef

Singh, S., Kumar, N., Verma, R., & Nehra, A. (2020). The safety and efficacy of adjunctive 20-Hz repetitive transcranial magnetic stimulation for treatment of negative symptoms in patients with schizphrenia: A double-blind, randomized, sham-controlled study. Indian Journal of Psychiatry, 62, 21–29.CrossRef

Smith, R. C., Leucht, S., & Davis, J. M. (2019). Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl), 236, 545–559.CrossRef

Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., et al. (2017). Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums, 22, 415–426.CrossRef

Stiekema, A. P. M., Van Dam, M. T., Bruggeman, R., Redmeijer, J. E., Swart, M., Dethmers, M., et al. (2020). Facilitating recovery of daily functioning in people with a severe mental illness who need longer-term intensive psychiatric services: Results from a cluster randomized controlled trial on cognitive adaption training delivered by nurses. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbx135.

Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correl, C. U. l., & Tiihonen, J. (2020). 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62.250 patients with schizophrenia (FIN20). World Psychiatry, 19, 61–68.

Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry, 74, 686–693.CrossRef

Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. American Journal of Psychiatry, 173, 600–606.CrossRef

Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correl, C. U., & Transkanen, A. (2019). Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry, 76, 499–507.CrossRef

Van der Moolen, A. E. G. M., Slooff, C., Bruggeman, R., & Knegtering, H. (2019). Psycho-educatie. In W. Cahn, I. Myin-Germeys, R. Bruggeman, L. De Haan (Red.), Handboek Schizofrenie Spectrumstoornissen. Utrecht: De Tijdstroom.

Van Dijk, F., De Wit, I., Blankers, M., Sommer, I., & De Haan, L. (2018). The personal antipsychotic choice index. Pharmacopsychiatry., 51, 89–99.CrossRef

Van Es, F. (2018). Biologische interventies. In De psychiater komt over de brug. Handreiking voor psychiaters, Projectgroep PvA (EPA redactie). Utrecht: Nederlandse Vereniging voor Psychiatrie.

Veerman, S. R. T., Schulte, P. F. J., & De Haan, L. (2017a). Treatment for negative symptoms in schizophrenia:a comprehensive review. Drugs, 17, 1423–1459.CrossRef

Veerman, S. R., Schulte, P. F., Deijen, J. B., & De Haan, L. (2017b). Adjunctive memantine in clozapine-treated refractory schizophrenia: An open-label 1-year extension study. Psychological Medicine, 47, 363–375.CrossRef

Ventura, J., Subotnik, K. L., Gitlin, M. J., Gretchen Doorly, D., Ered, A., Villa, K. F., et al. (2015). Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophrenia Research, 161, 407–413.CrossRef

Vermeulen, J., Van Rooijen, G., Doedens, P., Numminen, E., Van Tricht, M., & De Haan, L. (2017). Antipsychotic medication and long-term mortality risk in patients with schizophrenia; A systematic review and meta-analysis. Psychological Medicine, 47, 2217–2228.CrossRef

Vermeulen, J. M., Van Rooijen, G., Van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & De Haan, L. (2019). Clozapine and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophrenia Bulletin, 45, 315–329.

Voss, B., Thienel, R., Leucht, S., & Kircher, T. (2008). Therapy of cognitive deficits in schizophrenia with cholineesterase inhibitors, a systematic overview. Nervenarzt., 79, 47–48.CrossRef

Wagner, E., Honer, W. G., Sommer, I. E., Koops, S., Blumberger, D. M., Daskalakis, Z. J., et al. (2020). Repetitive trancranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. World Journal of Biological Psychiatry, 13, 1–13.CrossRef

Wang, G., Zheng, W., Li, X. B., Wang, S. B., Cai, D. B., Yang, X. H., et al. (2018). ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research, 105, 23–32.

Wang, J., Zhou, Y., Gan, H., Pang, J., Li, H., Wang, J., et al. (2017). Efficacy towards negative symptoms and satefy of repetitive transcranial magnetic stimulation treatment for patients with schizophrenia: A systematic review. Shanghai Arch Psychiatry, 29, 61–76.PubMed

Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-years randomized clinicial trial. JAMA Psychiatry, 9, 913–920.CrossRef

Zheng, W., Li, X. H., Yang, X. H., Cai, D. B., Ungvari, G. S., Ng, C. H., et al. (2018). Adjunctive memantine for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Psychological Medicine, 48, 72–81.CrossRef

Zhuo, K., Tang, Y., Song, Z., Wang, Y., Wanf, J., Qian, Z., et al. (2019). Repetitive transcaranial magnetic stimulations as adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: A randomized, double-blind, sham controles trial. Neuropsychiatric Disease and Treatment, 8, 1141–1150.CrossRef

Titel: Medicamenteuze en andere biologische behandelstrategieën bij mensen met een psychotische kwetsbaarheid
Auteurs: Dr. S. K. Spoelstra
Drs. F. D. van Es
Prof. dr. L. de Haan
Prof. dr. R. Bruggeman
Dr. H. Knegtering
Uitgeverij: Bohn Stafleu van Loghum
Boek: Ernstige psychiatrische aandoeningen
Print ISBN: 978-90-368-2585-6

Elektronisch ISBN: 978-90-368-2586-3

Copyright: 2021
DOI: https://doi.org/10.1007/978-90-368-2586-3_7

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen